
Camrelizumab enhances survival in advanced NPC with manageable toxicity. A phase 3 trial (n=450) found that adjuvant camrelizumab improved 3-year event-free survival (86.9% vs. 77.3%; HR=0.56, P=.01) after chemoradiotherapy. Grade 3/4 adverse events were higher (11.2% vs. 3.2%), but quality of life remained stable. These findings support camrelizumab as a promising adjuvant therapy for locoregionally advanced nasopharyngeal carcinoma.
Like
Save
Share